Product Details
| Alternative Name: | Apo-2L, TNFSF 10, CD253 |
| |
| MW: | ~28kDa |
| |
| Source: | Produced in E. coli. The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag. |
| |
| UniProt ID: | P50591 |
| |
| Concentration: | 0.1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥90% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Associates of Cape Cod). |
| |
| Species reactivity: | Human, Mouse
|
| |
| Specificity: | Binds to human and mouse TRAIL receptors and human osteoprotegerin (OPG). |
| |
| Biological Activity: | Induces apoptosis if applied with the cross-linking enhancer (Prod. No. ALX-804-034); see also TRAIL, Soluble (human) (recombinant) Set (Prod. No. ALX-850-018). Note: rhsTRAIL does not significantly induce apoptosis in the absence of an enhancer. |
| |
| Applications: | ELISA
|
| |
| Application Notes: | ELISA: binds to human TRAIL receptors and human osteoprotegerin (OPG) at 10-100 ng/ml. |
| |
| Reconstitution: | Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
| |
| Technical Info/Product Notes: | Historical data has shown that Fas induces apoptosis in a concentration range of 1-100ng/ml if applied with the cross-linking enhancer (Prod. No. ALX-804-034). |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
SDS PAGE Analysis: Lane 1: MW Marker, Lane 2: 1μg TRAIL.
Please mouse over
Product Literature References
The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer: R. Mandal, et al.; Cell. Mol. Life Sci.
79, 597 (2022),
Abstract;
XIAP promotes melanoma growth by inducing tumour neutrophil infiltration: M. Daoud, et al.; EMBO Rep.
23, e53608 (2022),
Abstract;
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1: A. Makowska, et al.; Cancer Immunol. Immunother.
70, 323 (2021),
Abstract;
Full Text
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment: S. Busche, et al.; Cell Death Dis.
12, 736 (2021),
Abstract;
The Mitochondrial Ca2+ Overload via Voltage-Gated Ca2+ Entry Contributes to an Anti-Melanoma Effect of Diallyl Trisulfide: C. Nakagawa, et al.; Int. J. Mol. Sci.
21, 491 (2020),
Abstract;
Full Text
Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling: S. Fullsack, et al.; Cell Death Dis.
10, 122 (2019),
Application(s): TRAIL treatment to stimulate TRAIL-related apoptotic gene expression,
Abstract;
Full Text
Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5: A. Fassl, et al.; Cell Death Dis.
6, e1921 (2015),
Abstract;
Full Text
Death receptor 5 signaling promotes hepatocyte lipoapoptosis: S.C. Cazanave, et al.; J. Biol. Chem.
286, 39336 (2011),
Abstract;
A role for cFLIP in B cell proliferation and stress MAPK regulation: H. Zhang, et al.; J. Immunol.
182, 207 (2009),
Abstract;
Full Text
Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death: F. Meslin, et al.; Cancer Res.
67, 10910 (2007),
Abstract;
Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy: C. Gajate & F. Mollinedo; J. Biol. Chem.
280, 11641 (2005),
Abstract;
Full Text
NF-κB signals induce the expression of c-FLIP: O. Micheau, et al.; Mol. Cell. Biol.
21, 5299 (2001),
Abstract;
Full Text
The cytokines tumor necrosis factor α (TNF-α) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the h: J.R. Basile, et al.; J. Biol. Chem.
276, 22522 (2001),
Abstract;
Full Text
Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-kappa B essential modulator (NEMO)/IKKgamma: D. Siegmund, et al.; J. Biol. Chem.
276, 43708 (2001),
Abstract;
Full Text
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy: A.M. Chinnaiyan, et al.; PNAS
97, 1754 (2000),
Abstract;
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2: M.R. Sprick, et al.; Immunity
12, 599 (2000),
Abstract;
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule: N. Holler, et al.; Nat. Immunol.
1, 489 (2000),
Abstract;
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity: P. Schneider, et al.; J. Exp. Med.
187, 1205 (1998),
Abstract;
Characterization of two receptors for TRAIL: P. Schneider, et al.; FEBS Lett.
416, 329 (1997),
Abstract;
Inhibition of death receptor signals by cellular FLIP: M. Irmler, et al.; Nature
388, 190 (1997),
Abstract;
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors: M. Thome, et al.; Nature
386, 517 (1997),
Abstract;
Related Products
